Carotegrast methyl - EA Pharma

Drug Profile

Carotegrast methyl - EA Pharma

Alternative Names: AJM 300

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ajinomoto
  • Developer EA Pharma
  • Class Anti-inflammatories; Quinazolines; Small molecules
  • Mechanism of Action Integrin alpha4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • No development reported Crohn's disease

Most Recent Events

  • 07 Sep 2017 Phase-III development for Ulcerative colitis is ongoing in Japan (PO) (EA Pharma pipeline, September 2017)
  • 10 Jun 2016 Chemical structure information added
  • 31 Mar 2015 Ajinomoto Pharmaceuticals and Kissei Pharmaceutical agree to co-develop and commercialise carotegrast methyl in Japan for Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top